Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to ...

Biogen’s second quarter delivered results that exceeded Wall Street’s revenue and profit expectations, a performance that was ...

Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Thursday morning. Here’s what you need to know. Biogen beat analysts’ revenue expectations by 8.6% last quarter, reporting revenues ...

NasdaqGS:BIIB 1 Year Share Price vs Fair Value Explore Biogen's Fair Values from the Community and select yours ...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

We came across a bullish thesis on Biogen Inc. on r/Valueinvesting subreddit by U/Lobyous. In this article, we will summarize ...

Biogen Inc. Quarterly stock financials by MarketWatch. View the latest BIIB financial statements, income statements and financial ratios.

Investors in Biogen Inc (Symbol: BIIB) saw new options become available this week, for the July 2025 expiration. One of the key data points that goes into the price an option buyer is willing to ...

Biogen will invest $2 billion more in its existing manufacturing plants in North Carolina, the drugmaker said on Monday, as ...